Update on Rifampin and Rifabutin Drug Interactions

@article{Baciewicz2008UpdateOR,
  title={Update on Rifampin and Rifabutin Drug Interactions},
  author={Anne M. Baciewicz and Cary R. Chrisman and Christopher K Finch and Timothy H Self},
  journal={The American Journal of the Medical Sciences},
  year={2008},
  volume={335},
  pages={126-136}
}
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus–related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Examples of clinically relevant… Expand
Update on rifampin, rifabutin, and rifapentine drug interactions
TLDR
To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Expand
Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.
TLDR
The general mechanism of action, absorption, metabolization, and excretion of the drugs used to treat multidrug resistant tuberculosis (aminoglycosides, fluoroquinolones, cycloserine/terizidone, ethionamide, capreomycin, and para-aminosalicylic acid) are described. Expand
Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model‐Based Approaches to Drug–Drug Interaction Trial Design
We studied the time course for the reversal of rifampin's effect on the pharmacokinetics of oral midazolam (a cytochrome P450 (CYP) 3A4 substrate) and digoxin (a P‐glycoprotein (P‐gp) substrate).Expand
Inability to Achieve a Therapeutic INR Value While on Concurrent Warfarin and Rifampin
TLDR
Clinical pharmacology suggests that a 2to 3-fold increase in warfarin dose may be necessary during concurrent therapy to account for this drug-drug interaction, but does not offer any guidance regarding how quickly the dose must be reduced following cessation of rifampin therapy. Expand
Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir
TLDR
Doubling the raltegravir dose to 800 mg when coadministered with rifampin therefore compensates for the effect of rifampsin on ralTEgravIR exposure (AUC0-12); however, caution should be used, since rAlteg Gravir trough concentrations in the presence of rIFampin are likely to be at the lower limit of clinical experience. Expand
Phenytoin‐Rifampin Drug Interaction in a Hypoalbuminemic, Renal Failure Patient: A Complex Clinical Case
TLDR
The need for appropriate management of phenytoin in a patient with complicated needs for pharmacotherapy is highlighted and the first description of this drug interaction in 20 years is described. Expand
Overcoming the effect of rifampin on the tacrolimus metabolism by itraconazole administration in an allogeneic hematopoietic stem cell transplant recipient
TLDR
This case presents a case in which rifampin was coadministered with tacrolimus after allogeneic HSCT, and administration of oral-solution itraconazole successfully offset the effect of rifampsin on the tac rolimus metabolism, resulting in the achievement of a therapeutic blood level of tacro Limus. Expand
Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile
TLDR
A model-based approach was used to predict the magnitude of DDI with RIF and rifabutin for 217 cytochrome P450 (CYP) substrates, finding that DDI caused by low-dose RIF were twice more potent than those caused by RBT. Expand
Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature
TLDR
The present case exemplifies the influence of rifampicin therapy on warfarin dosage requirements and the increased risk of bleeding after rifampsicin discontinuation, and highlights the need for warFarin weekly monitoring after stopping rifampingicin until the maintenance dose of war Farfarin has decreased to the amount administered before rifAMPicin use. Expand
Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
TLDR
Macitentan co-administered with Cs or rifampin was well tolerated and no marked differences in uptake rates of macitentan and ACT-132577 between the wild-type and OATP over-expressing cells over the concentration range tested were demonstrated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
Update on rifampin drug interactions, III.
TLDR
To avoid reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Expand
Rifampin and rifabutin drug interactions: an update.
TLDR
Clinicians need to be cognizant of rifampin and rifabutin interactions to avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampsin is added to or discontinued from medication regimens. Expand
Update on rifampin drug interactions. II.
TLDR
Clinically important drug interactions have been documented between rifampin and numerous other drugs, such as oral anticoagulants, oral contraceptives, cyclosporine, digitalis, and ketoconazole. Expand
Update on rifampin drug interactions.
TLDR
New rifampin interactions have been described for cyclosporine, ketoconazole, chloramphenicol, beta-blockers, verapamil, and phenytoin that seem to be of clinical significance. Expand
Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report.
TLDR
Close monitoring of tacrolimus levels and frequent dose adjustments are required whenever rifampin is administered posttransplant, regardless of P450 inhibitors used, to optimize allograft function. Expand
Rifampin drug interactions.
TLDR
Two therapeutic agents (ethionamide and protionamide) not mentioned that may have serious to potentially fatal consequences when used with rifampin that are used as "second-line" antituberculosis agents and also used for the treatment of leprosy are not mentioned. Expand
Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease
TLDR
HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial infection exhibit decreased bioavailability of antituberculosis drugs. Expand
Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate‐glucuronosyltransferase
TLDR
The effect of rifampin on MPA metabolism can be explained by simultaneous induction of renal, hepatic, and gastrointestinal uridine diphosphate–glucuronosyltransferases and organic anion transporters with subsequent functional inhibition of enterohepatic recirculation of MPA. Expand
Effect of Rifampin on Plasma Concentrations of Mefloquine in Healthy Volunteers
TLDR
The aim was to study the effect of rifampin on the pharmacokinetics of me floquine, and explore a possible role of CYP3A4 on mefloquine metabolism. Expand
Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers
TLDR
The aim of this investigation was to study the possible pharmacokinetic interaction between rifampin and praziquantel. Expand
...
1
2
3
4
5
...